Third Positive Phase 2 Proof-of-Concept Study for VX-150 Further Validates the Potential Role of NaV1.8 Inhibition

 

December 18, 2018

Today we announced positive results of a Phase 2 study of the investigational NaV1.8 inhibitor VX-150 in patients with pain caused by small fiber neuropathy. The study met its primary endpoint and showed that treatment with VX-150 demonstrated statistically significant and clinically meaningful pain reduction, as measured by the within-group change from baseline in the weekly average of daily pain intensity on the 11-point numeric rating scale (NRS) at Week 6. VX-150 was generally well tolerated in this study.

This Phase 2 study in patients with small fiber neuropathy is the third positive proof-of-concept study for VX-150 and provides further validation of the potential role of NaV1.8 inhibition in the treatment of multiple pain conditions. A Phase 2b dose-ranging study of VX-150 following bunionectomy surgery is currently ongoing to support potential pivotal development. Additionally, the company is advancing multiple pain molecules through late-stage preclinical development and anticipates initiating clinical development with the first of these molecules in 2019.